Abnormal Expression of the Pre-mRNA Splicing Regulators SRSF1, SRSF2, SRPK1 and SRPK2 in Non Small Cell Lung Carcinoma

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gout, Stephanie ^a,b   Brambilla, Elisabeth ^a,b,c   Boudria, Asma ^a,b   Drissi, Romain ^a,b   Lantuejoul, Sylvie ^a,b,c   Gazzeri, Sylvie ^a,b   Eymin, Beatrice ^a,b  

^a INSERM   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FIBRONECTIN; MESSENGER RNA PRECURSOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P42; PROTEIN SRPK1; PROTEIN SRPK2; PROTEIN SRSF1; PROTEIN SRSF2; SERINE ARGININE RICH PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CANCER STAGING; CARCINOMA CELL; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVATION; ENZYME INDUCTION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESENCHYME; PHENOTYPE; PREDICTION; PROTEIN DEFECT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; RNA SPLICING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PACLITAXEL; PHENOTYPE; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOPROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84867364542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046539     Document Type: Article

References (45)

1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature. 456: 470-476.
2. Srebrow A, Kornblihtt AR, (2006) The connection between splicing and cancer. J Cell Sci. 119: 2635-2641.
3. Venables JP, (2004) Aberrant and alternative splicing in cancer Cancer Res. 64: 7647-7654.
4. Brinkman BM, (2004) Splice variants as cancer biomarkers. Clin Biochem. 37: 584-94.
5. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, et al. (2008) Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res. 36: 6535-6547.
6. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, et al. (2011) Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol. 31: 138-150.
7. Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, et al. (2006) E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ. 13: 260-272.
8. Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, et al. (2008) E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 15: 1815-1823.
9. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, et al. (2010) The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene. 29: 5392-5403.
10. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, et al. (2011) Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 30: 510-523.
11. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, et al. (2004) Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology. 44: 54-63.
12. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H, (1998) Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res. 58: 1108-1110.
13. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, et al. (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 20: 4041-4049.
14. Pio R, Montuenga LM, (2009) Alternative splicing in lung cancer. J Thorac Oncol. 4: 674-678.
15. Kim E, Goren A, Ast G, (2008) Insights into the connection between cancer and alternative splicing. Trends Genet. 24: 7-10.
16. Hastings ML, Krainer AR, (2001) Pre-mRNA splicing in the new millennium. Curr Opin Cell Biol. 13: 302-309.
17. Long JC, Caceres JF, (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 417: 15-27.
18. Zahler AM, Lane WS, Stolk JA, Roth MB, (1992) SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev. 6: 837-847.
19. Wu JY, Maniatis T, (1993) Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell. 75: 1061-1070.
20. Xiao SH, Manley JL, (1998) Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2. EMBO J. 17: 6359-6367.
21. Gui JF, Lane WS, Fu XD, (1994) A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature. 369: 678-82.
22. Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, et al. (1996) The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J. 15: 265-275.
23. Ko TK, Kelly E, Pines J, (2001) CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J Cell Sci. 114: 2591-2603.
24. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, et al. (2005) Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol. 12: 1037-1044.
25. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 14: 185-193.
26. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, Lopez-Picazo JM, et al. (2010) The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res. 16: 4113-4125.
27. Travis WD, Brambilla E, Muller-Hemerlink HK, Harris CC (2004) World Health Organization classification of tumours. Pathology and Genetics of tumours of the lung, pleura, thymus and heart. IARC Press: Lyon 2004.
28. Caceres JF, Screaton GR, Krainer AR, (1998) A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 12: 55-66.
29. Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, et al. (2011) Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 92: 1794-1804.
30. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, et al. (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19: 220-228.
31. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, et al. (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20: 881-890.
32. Schwerk C, Schulze-Osthoff K, (2005) Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 19: 1-13.
33. Piekielko-Witkowska A, Wiszomirska H, Wojcicka A, Poplawski P, Boguslawska J, et al. (2010) Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors. PLoS One. 5: e13690.
34. Stickeler E, Kittrell F, Medina D, Berget SM, (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene. 18: 3574-3582.
35. Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, et al. (2004) Expression of splicing factors in human ovarian cancer. Oncol Rep. 11: 1085-1090.
36. Mole S, McFarlane M, Chuen-Im T, Milligan SG, Millan D, et al. (2009) RNA splicing factors regulated by HPV16 during cervical tumour progression. J Pathol. 219: 383-391.
37. Hayes GM, Carrigan PE, Beck AM, Miller LJ, (2006) Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 66: 3819-3827.
38. Hayes GM, Carrigan PE, Miller LJ, (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 67: 2072-2080.
39. Jang SW, Yang SJ, Ehlen A, Dong S, Khoury H, et al. (2008) Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res. 68: 4559-4570.
40. Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR, (1997) Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol. 138: 225-238.
41. Neal JW, (2010) Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist. 15: 3-5.
42. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, et al. (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 21: 2023-2028.
43. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC, (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 28: 5311-5320.
44. Xiao R, Sun Y, Ding JH, Lin S, Rose DW, et al. (2007) Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol. 27: 5393-5402.
45. Ghigna C, De Toledo M, Bonomi S, Valacca C, Gallo S, et al. (2010) Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol. 7: 495-503.